EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Nov 4, 2009

Story Timeline: 21 days

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data... [read full story]

Add Comment

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer...

drugs.com

Nov 4, 2009

First article on this story:

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer...

prnewswire.com

Nov 4, 2009

Selected publications with coverage of this story:

news-medical.net prnewswire.com drugs.com

FROM US SOURCES
- SHOW ARTICLES:
- FROM UK SOURCES
- FROM INDIAN SOURCES
- FROM ALL SOURCES

Show articles from all sources

Male Health, Pharmaceuticals, Ambulatory Health Care, Cancer by Body Location, Medicines & Remedies, Scientific Discoveries, Health Care, Cancers, Cancer Treatments, Patients, Scientists, Cancer Therapy, Prostate Cancer, Lung Cancer, Medical Research, ACCO Brands

NewstinMap

Click to Open NewstinMap —

Visual Navigation

My Newstin

Context

ACCO Brands

Intelligent Data Fusion

About Us

Visit our corporate homepage to learn more about our company and products.

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer...

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer...

Related categories

International Editions